# BrightSpring Health Services account plan

> BrightSpring Health Services is a US home and community-based pharmacy and provider services platform: $12.9 billion FY2025 revenue.

## At a glance

BrightSpring Health Services, headquartered in Louisville, Kentucky, delivers complementary pharmacy and provider services to complex Senior and Specialty patients, largely funded by Medicare, Medicaid and commercial insurance, in home and community settings. It operates in all 50 states, Puerto Rico and Canada and serves approximately 500,000 patients daily through approximately 12,700 clinical providers and pharmacists (Q3 2026). FY2025 revenue grew 28.2% to $12.9 billion, Adjusted EBITDA rose 34.2% to $617.6 million and net income from continuing operations was $104.8 million; it had over 23,500 full-time equivalent employees at December 31, 2025. The company is listed and KKR remains a significant shareholder; Jon Rousseau is Chairman, President and CEO.

## Business units

- **Infusion and Specialty Pharmacy** (70.5% of FY2025 revenue ($9,095.9 million)): Infused, injectable and oral therapies at home and in clinics, with a strong position in oral oncology and rare drugs. Revenue grew 39.4% in 2025 and 33.8% to $3,179.8 million in Q3 2026; 162 limited distribution drugs are now supported. Investments continue in infusion suites and clinic upgrades.
- **Home and Community Pharmacy** (18.2% of FY2025 revenue ($2,349.9 million)): Local pharmacy service for senior living, behavioral group homes, hospice, skilled nursing facilities and hospitals, plus the CCRx transitional medication program. Q3 2026 revenue fell 6.3% to $552.6 million because of the Inflation Reduction Act, though EBITDA grew.
- **Home Health Care** (5.9% of FY2025 revenue ($767.9 million)): Home health, hospice and home-based primary care for Seniors. Q3 2026 revenue rose 52.4% to $288.3 million and average daily census 57.6% to 47,256, helped by the Amedisys and LHC branches.
- **Personal Care** (3.1% of FY2025 revenue ($402.2 million)): Home care support with activities of daily living for Seniors, mostly Medicaid-funded; Q3 2026 revenue was $110.7 million (+8.1%).
- **Rehab Care** (2.3% of FY2025 revenue ($294.7 million)): Physical, speech, occupational therapy and ABA for brain and spinal cord injuries, stroke, pediatric neuro conditions and autism, mostly at home. Q3 2026 revenue was $81.8 million (+8.3%).

## Strategic priorities

- **Specialty and infusion growth**: Win limited distribution drug launches (19 year-to-date in 2026) and expand acute and chronic infusion at home and in suites.
- **Home-based primary care and value-based care**: BrightSpring was selected for the REACH ACO Medicare program from January 1 and aims within 5 to 10 years to become a national brand for primary care in the community.
- **Integrated care**: Deliver multiple pharmacy and provider services to the same patients, today approximately 10,000, using home-based primary care, transitional care and the Clinical (Nursing) Hub.
- **Volume, efficiency and accretive M&A**: The CEO's playbook combines sales investment, Lean Sigma, technology and AI projects, with tuck-in acquisitions in home health, hospice, rehab, primary care and infusion.
- **Deleveraging and cash generation**: Leverage fell to 1.79x at September 30, 2026 and management expects at least $700 million of operating cash flow in 2026.

## Latest results

In Q3 2026 (quarter ended September 30, 2026) revenue grew 26.4% to $4,213.2 million and Adjusted EBITDA 42.0% to $227.8 million; net income from continuing operations was $100.8 million and Adjusted EPS $0.54. Pharmacy Solutions revenue rose 25.8% to $3,732.4 million with segment EBITDA of $202.0 million, and Provider Services revenue 31.0% to $480.8 million, of which $76.1 million came from the Amedisys and LHC branches. The company raised full-year 2026 guidance to revenue of $15,900 million to $16,125 million and Adjusted EBITDA of $850 million to $860 million, and reiterated at least 15% to 20% organic Adjusted EBITDA growth for 2027.

## Investments and deals

- **Community Living divestiture**: The I/DD Community Living business was sold to National Mentor Holdings for $835.0 million, closing on March 30, 2026; proceeds helped repay $300.0 million of term debt.
- **Amedisys and LHC branches**: 110 home health and hospice branches in 18 states bought from Amedisys and UnitedHealth Group for $246.4 million in December 2025; expected to add approximately $35 million of Adjusted EBITDA in 2026.
- **Technology and AI**: New EMR and ERP systems, a cloud data lake and BI platform, robotic process automation and AI-assisted recruiting; AI projects target documentation, medication review, HR and hiring, with returns expected more fully in 2027.
- **Continuous improvement**: PMO-led continuous improvement delivered approximately $84.7 million of annual savings in 2025, reinvested in wages, quality, technology and growth.
- **Refinancing and buybacks**: A new $2,214.9 million Tranche B-6 term loan was set up on May 28, 2026, and $120.0 million of shares were repurchased in 2026.

## Challenges and risks

- **Inflation Reduction Act impact**: Approximately $200 million of IRA impact in specialty and infusion and approximately $175 million in home and community pharmacy were expected for 2026.
- **Government reimbursement**: Medicare and Medicaid rate changes, Medicare Part D and PBM contracts are key risks; Medicare Part D was 29.6% and Medicaid 11.4% of Q3 2026 revenue.
- **Clinical staffing**: Recruitment and retention of nurses, pharmacists, therapists and caregivers is a stated risk; personal care demand continues to outstrip the company's ability to provide it.
- **Indebtedness**: Long-term debt net of current portion was $2,146,779 thousand at September 30, 2026.

## What leadership says

> "We could do $400 million of EBITDA in M&A tomorrow. If we wanted to." — Jon Rousseau, Chairman, President and CEO, Q3 2026 earnings call, October 30, 2026

> "the household name and national brand for primary care out in the community" — Jon Rousseau, Chairman, President and CEO, Q3 2026 earnings call, October 30, 2026

> "the highest service levels in the industry and the best cost per fill" — Jon Rousseau, Chairman, President and CEO, Q3 2026 earnings call, on Home and Community Pharmacy, October 30, 2026

> "the annualized revenue contribution from the 2026 launches is tracking ahead" — Jennifer Phipps, CFO, Q3 2026 earnings call, October 30, 2026


## Where a supplier can help

- **AI for documentation and medication review**: Tied to the technology and AI investment: tools that automate clinical documentation, medication review and hiring fit projects the company expects to pay back in 2027.
- **Clinical recruiting and retention**: Tied to the clinical staffing challenge: recruiting, scheduling and workforce platforms for nurses, pharmacists and caregivers.
- **Pharmacy cost per fill**: Tied to the Home and Community Pharmacy goal of the best cost per fill and the IRA headwind: automation, logistics and intake systems that cut dispensing cost.
- **Acquisition integration**: Tied to the M&A playbook: IT and back-office integration services for acquired home health and hospice branches.
- **Value-based care infrastructure**: Tied to the REACH ACO and primary care priority: population health analytics, care coordination and virtual care tools.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [BrightSpring Health Services Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1865782/000119312526079454/btsg-20251231.htm)

Annual report · 2026-02-27

- BrightSpring is a US home and community-based healthcare services platform combining pharmacy and provider services for complex Senior and Specialty patients; it serves over 465,000 patients daily in all 50 states through approximately 10,500 clinical providers and pharmacists, with over 23,500 full-time equivalent employees (Dec 31, 2025).
- FY2025 revenue grew 28.2% to $12.9 billion; Adjusted EBITDA rose 34.2% to $617.6 million; net income from continuing operations was $104.8 million versus a $68.9 million loss in 2024.
- Two segments: Pharmacy Solutions ($11.4 billion, 88.7% of revenue, segment EBITDA $543.5 million, +37.7%) and Provider Services ($1.5 billion, 11.3%, segment EBITDA $232.7 million, +13.3%).
- Infusion and Specialty Pharmacy is the growth engine: revenue $9,095.9 million (+39.4%), 149 limited distribution oncology drugs in the market with 18 more to launch.
- Portfolio reshaped: the Community Living business (I/DD services) is being sold to National Mentor Holdings for $835 million (expected close Q1 2026, reported as discontinued operations); three Provider Services acquisitions in 2025, including the Amedisys and LHC branches (110 branches, $246.4 million).
- Payor mix: Medicare Part D 31.7%, commercial insurance 25.6%, Medicare Part C 18.7%, Medicaid 11.6% of 2025 revenue; no payor above 35%.
- Strategy: integrated and value-based care built on home-based primary care, the CCRx transitional medication program and a Clinical (Nursing) Hub; ACO shared savings arrangements entered in the past year.
- Operations and tech: PMO-led continuous improvement delivered approximately $84.7 million of annual savings in 2025; investments in EMR/ERP, a cloud data lake and BI platform, robotic process automation and AI-assisted hiring.
- Main risks: Medicare/Medicaid rate changes, Medicare Part D and PBM reimbursement, staffing of nurses and pharmacists, regulatory compliance, and $2,521.3 million outstanding under the First Lien Term Loan; KKR remains a significant shareholder.

### [BrightSpring Health Services Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1865782/000186578226000012/btsg-20260930.htm)

Interim report · 2026-10-30

- Q3 2026 revenue grew 26.4% to $4.2 billion; Adjusted EBITDA rose 42.0% to $227.8 million; net income from continuing operations was $100.8 million; diluted EPS $0.46, Adjusted EPS $0.54.
- Pharmacy Solutions revenue $3,732.4 million (+25.8%, 88.6% of revenue), segment EBITDA $202.0 million (+43.3%); gross margin 8.5% versus 8.3%.
- Specialty and Infusion Pharmacy revenue $3,179.8 million (+33.8%) on specialty branded drug volumes; Home and Community Pharmacy fell 6.3% to $552.6 million because of the Inflation Reduction Act.
- Provider Services revenue $480.8 million (+31.0%), of which $76.1 million came from the Amedisys and LHC branches; Home Health Care average daily census up 57.6% to 47,256.
- The Community Living divestiture closed on March 30, 2026; proceeds of $810.9 million were used in part to repay $300.0 million of term debt and refinance into a $2,214.9 million Tranche B-6.
- Company leverage 1.79x at September 30, 2026; cash $717,840 thousand; Total Liquidity $1,193,981 thousand; $120.0 million of share repurchases in 2026.
- About 500,000 patients served daily through approximately 12,700 clinical providers and pharmacists; multiple pharmacy and provider services delivered to approximately 10,000 patients.

### [BrightSpring Health Services Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance](https://www.sec.gov/Archives/edgar/data/1865782/000186578226000011/btsg-ex99_1.htm)

Interim report · 2026-10-30

- Q3 2026 net revenue $4,213 million (+26.4%), gross profit $519 million (+32.3%), net income from continuing operations $101 million, Adjusted EBITDA $228 million (+42.0%).
- Pharmacy Solutions revenue $3,732 million (+26%), segment EBITDA $202 million (+43%); Provider Services revenue $481 million (+31%), segment EBITDA $79 million (+30%).
- Full-year 2026 guidance raised: revenue $15,900 million to $16,125 million (23.2% to 24.9% growth) and Adjusted EBITDA $850 million to $860 million (37.6% to 39.3% growth).
- Segment guidance: Pharmacy $14,000 million to $14,200 million; Provider $1,900 million to $1,925 million.
- The Amedisys and LHC branches acquisition is expected to contribute approximately $35 million of Adjusted EBITDA in 2026.
- Leverage 1.79x at September 30, 2026, down from 2.15x at June 30, 2026; cash $717,840 thousand.
- CEO Jon Rousseau: BrightSpring is "well -positioned to make a greater and greater impact and deliver durable growth in 2027 and beyond".

### [BrightSpring (BTSG) Q3 2026 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/10/30/brightspring-btsg-q3-2026-earnings-call-transcript/)

Executive talk · Jon Rousseau, Chairman, President and Chief Executive Officer · 2026-10-30

- Q3 2026 revenue of $4.2 billion (+26%) and Adjusted EBITDA of $228 million (+42%); EPS of $0.54 up 80%; cash flow from operations of $204 million.
- Specialty and infusion revenue grew 34% on 29% script growth; 7 LDD launches in the quarter, 19 year-to-date, 162 LDDs now supported; 2026 launches outperforming the 2025 cohort.
- Home and Community Pharmacy revenue fell 6% to $553 million on an approximately $50 million IRA impact; full-year IRA impact approximately $200 million, yet EBITDA grew well into the double digits.
- Home health census up approximately 58%; the Amedisys/LHC branches contributed $76 million of revenue and are expected to add approximately $35 million of Adjusted EBITDA in 2026.
- Guidance raised to $15.9 billion to $16.125 billion revenue and $850 million to $860 million Adjusted EBITDA; 2027 organic Adjusted EBITDA growth of at least 15% to 20% reiterated.
- Leverage 1.79x; operating cash flow of at least $700 million expected for 2026; Rousseau says "We could do $400 million of EBITDA in M&A tomorrow" but favors tuck-ins and slightly larger deals.
- Selected for the REACH ACO Medicare program from January 1; ambition to be "the household name and national brand for primary care out in the community".
- AI investments target documentation, medication review, HR and hiring; returns from technology expected more fully in 2027.

### [BrightSpring (BTSG) Q4 2025 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/02/27/brightspring-btsg-earnings-call-transcript/)

Executive talk · Jon Rousseau, Chief Executive Officer · 2026-02-27

- FY2025 revenue $12.9 billion (+28%) and Adjusted EBITDA $618 million (+34%); margin 4.8%; operating cash flow $490 million; leverage down to 2.99x from 4.16x.
- Initial 2026 guidance: revenue $14.45 billion to $15.0 billion and Adjusted EBITDA $760 million to $790 million (23.1% to 27.9% growth), including approximately $30 million from Amedisys and LHC.
- Community Living sale expected to yield approximately $715 million of net after-tax proceeds, mainly for debt pay down.
- Amedisys/LHC: 107 branches for $239 million, funded from cash, with $345 million of 2025 pro forma revenue.
- Specialty and infusion revenue grew 43% in Q4; 24 LDD launches in 2025, 149 LDDs, 16 to 20-plus launches expected over 12 to 18 months; over 30 pharma hubs.
- 2026 headwinds: approximately $200 million IRA impact in specialty and infusion and approximately $175 million in home and community pharmacy, plus brand-to-generic conversions.
- Priorities: sales investments, Lean Sigma, technology and AI projects, about 30 new home and community pharmacy reps, expanding infusion suites; seven-year CAGR of 22% in revenue and 18% in Adjusted EBITDA.

## Questions about BrightSpring Health Services

### What does BrightSpring Health Services do?

BrightSpring provides pharmacy services (specialty, infusion and home and community pharmacy) and provider services (home health, hospice, primary care, rehab and personal care) to complex Senior and Specialty patients in home and community settings across the US.

### What is BrightSpring's revenue?

FY2025 revenue was $12.9 billion, up 28.2%, with Adjusted EBITDA of $617.6 million. 2026 guidance is $15,900 million to $16,125 million of revenue.

### How many employees does BrightSpring have?

It had over 23,500 full-time equivalent employees at December 31, 2025, and approximately 12,700 clinical providers and pharmacists as of Q3 2026.

### Who leads BrightSpring?

Jon Rousseau is Chairman, President and CEO; Jennifer Phipps is CFO.

### What is BrightSpring's strategy?

Grow specialty and infusion pharmacy, build home-based primary care and value-based care, integrate pharmacy and provider services for the same patients, and add tuck-in acquisitions while reducing leverage.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
